Drugs · Brain health technique
Methylene Blue / LMTM (Leuco-Methylthioninium)
Evidence grade: Experimental

A redox-active compound with mitochondrial and tau-modulating effects, historically used as a dye and in methemoglobinemia. Investigational formulations include methylene blue (USP form) and its derivative LMTM (TauRx Therapeutics), studied for Alzheimer’s and cognitive decline.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Neuroprotective & Disease-modifying Therapies
- Evidence grade
- Experimental
- Strength of evidence
- Low
- Cost
- High
- Effort
- Low
- Time commitment
- Low
How to practice Methylene Blue / LMTM (Leuco-Methylthioninium)
Only to be used under clinical supervision or in research contexts. Low-dose regimens (≤2 mg/kg) appear safe but not evidence-based for cognitive outcomes. Avoid self-administration and drug interactions with serotonergic agents. Await next-generation tau-targeted redox compounds for validated efficacy.
The evidence behind Methylene Blue / LMTM (Leuco-Methylthioninium)
Methylene blue helps mitochondria make energy and lowers oxidative stress. Methylene blue is an approved treatment for a rare blood disorder. Beyond that, the evidence is mixed. The biology is very plausible, but benefit for health or thinking in people is unproven. Methylene blue has risks too. Taken with SSRIs or MAOIs (two types of antidepressants), it can cause serotonin syndrome. The risk increases with higher doses.
Impact on brain health
In lab studies, methylene blue and its derivative LMTM also block tau from forming the clumps seen in Alzheimer's. Early small trials showed mild gains in memory and thinking, but large late-stage trials did not show meaningful effects.
Reviewed by BetterBrain's clinical advisors · Updated November 2026 · Our science
More Drugs techniques
Pair this with other habits from the same practice.

Evidence grade: Context Dependent
Anti-Amyloid Monoclonal Antibodies
FDA-approved biologic drugs that target beta-amyloid plaques to slow Alzheimer’s progression, including lecanemab (Leqembi®), donanemab (Kisunla™).

Evidence grade: Context Dependent
Antihypertensives
Medications that lower blood pressure to protect vascular and brain health, including ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), calcium channel blockers…

Evidence grade: Context Dependent
GLP-1 Receptor Agonists
A class of injectable or oral medications that mimic the hormone glucagon-like peptide-1 (GLP-1) to improve insulin sensitivity, suppress appetite, and reduce inflammation.
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.